AmCad BioMed Corporation(TW:4188)
NT$13.45-0.25 (-1.82%)
TW:4188
AmCad BioMed Corporation financials statements
NT$13.45
At close:-0.25 (-1.82%)
AmCad BioMed Corporation (4188) Ratios
AmCad BioMed Corporation Ratios
TW:4188's free cash flow for Q2 2026 was NT$-13.18M. For the 2026 fiscal year, TW:4188's free cash flow was increased by NT$0.00 and operating cash flow was NT$-13.18M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 22.62 | 16.63 | 13.35 | 13.15 | 15.33 |
| Quick Ratio | 21.11 | 15.43 | 12.32 | 12.30 | 14.52 |
| Cash Ratio | 1.36 | 0.71 | 1.21 | 1.72 | 2.24 |
| Solvency Ratio | -1.82 | -1.04 | -0.80 | -1.05 | -0.20 |
| Operating Cash Flow Ratio | -2.60 | -2.06 | -1.70 | -1.25 | -1.49 |
| Short-Term Operating Cash Flow Coverage | -35.84 | 0.00 | -368.13 | -185.83 | -581.61 |
| Net Current Asset Value | NT$ 388.11M | NT$ 386.93M | NT$ 291.19M | NT$ 325.80M | NT$ 363.82M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.01 | 0.02 | 0.03 | 0.02 | 0.02 |
| Debt-to-Equity Ratio | 0.01 | 0.02 | 0.04 | 0.02 | 0.03 |
| Debt-to-Capital Ratio | 0.01 | 0.02 | 0.04 | 0.02 | 0.03 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.19 | 1.22 | 1.35 | 1.30 | 1.27 |
| Debt Service Coverage Ratio | -39.62 | -191.18 | -108.31 | -118.75 | -33.73 |
| Interest Coverage Ratio | -999.49 | -359.24 | -438.90 | -463.90 | -186.42 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.08 | 0.19 | 0.27 | 0.20 | 0.28 |
| Net Debt to EBITDA | 0.36 | 0.20 | 0.59 | 1.00 | 5.17 |
| Profitability Margins | |||||
| Gross Profit Margin | 32.93% | 62.02% | 62.87% | 61.73% | 70.71% |
| EBIT Margin | -234.30% | -99.23% | -65.93% | -87.99% | -31.18% |
| EBITDA Margin | -182.40% | -64.80% | -39.17% | -59.39% | -9.86% |
| Operating Profit Margin | -288.97% | -121.77% | -82.73% | -88.07% | -31.29% |
| Pretax Profit Margin | -234.59% | -99.57% | -66.12% | -88.18% | -31.34% |
| Net Profit Margin | -183.06% | -95.24% | -69.44% | -86.79% | -29.77% |
| Continuous Operations Profit Margin | -234.54% | -99.57% | -66.12% | -88.18% | -31.34% |
| Net Income Per EBT | 78.03% | 95.65% | 105.02% | 98.43% | 94.99% |
| EBT Per EBIT | 81.18% | 81.77% | 79.93% | 100.12% | 100.17% |
| Return on Assets (ROA) | -8.95% | -7.28% | -8.84% | -9.66% | -4.15% |
| Return on Equity (ROE) | -10.69% | -8.89% | -11.91% | -12.60% | -5.29% |
| Return on Capital Employed (ROCE) | -14.55% | -9.66% | -11.06% | -10.31% | -4.55% |
| Return on Invested Capital (ROIC) | -14.51% | -9.58% | -10.96% | -10.07% | -4.29% |
| Return on Tangible Assets | -9.90% | -8.05% | -10.32% | -11.33% | -4.86% |
| Earnings Yield | -5.99% | -3.92% | -3.13% | -6.30% | -2.48% |
| Efficiency Ratios | |||||
| Receivables Turnover | 3.25 | 2.57 | 5.74 | 13.49 | 14.51 |
| Payables Turnover | 15.50 | 7.37 | 13.17 | 26.86 | 23.16 |
| Inventory Turnover | 0.75 | 0.67 | 0.97 | 1.01 | 1.18 |
| Fixed Asset Turnover | 0.40 | 0.64 | 0.79 | 0.77 | 0.97 |
| Asset Turnover | 0.05 | 0.08 | 0.13 | 0.11 | 0.14 |
| Working Capital Turnover Ratio | 0.08 | 0.15 | 0.21 | 0.17 | 0.23 |
| Cash Conversion Cycle | 577.61 | 637.08 | 412.75 | 374.49 | 317.92 |
| Days of Sales Outstanding | 112.30 | 142.03 | 63.57 | 27.05 | 25.16 |
| Days of Inventory Outstanding | 488.85 | 544.56 | 376.90 | 361.02 | 308.52 |
| Days of Payables Outstanding | 23.55 | 49.51 | 27.72 | 13.59 | 15.76 |
| Operating Cycle | 601.16 | 686.59 | 440.47 | 388.08 | 333.68 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.74 | -0.90 | -0.76 | -0.64 | -0.73 |
| Free Cash Flow Per Share | -0.75 | -0.95 | -0.77 | -0.65 | -0.78 |
| Dividend Paid and CapEx Coverage Ratio | -126.17 | -17.01 | -141.98 | -55.69 | -16.69 |
| Capital Expenditure Coverage Ratio | -126.17 | -17.01 | -141.98 | -55.69 | -16.69 |
| Operating Cash Flow Coverage Ratio | -9.91 | -4.77 | -2.87 | -3.26 | -2.63 |
| Operating Cash Flow to Sales Ratio | -1.55 | -0.98 | -0.64 | -0.55 | -0.45 |
| Free Cash Flow Yield | -5.10% | -4.26% | -2.89% | -4.10% | -4.01% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -16.70 | -25.40 | -32.11 | -15.79 | -40.31 |
| Price-to-Sales (P/S) Ratio | 30.58 | 24.29 | 22.22 | 13.77 | 12.00 |
| Price-to-Book (P/B) Ratio | 1.79 | 2.27 | 3.81 | 2.00 | 2.13 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -19.62 | -23.49 | -34.61 | -24.39 | -24.93 |
| Price-to-Operating Cash Flow Ratio | -19.78 | -24.88 | -34.86 | -24.83 | -26.43 |
| Price-to-Earnings Growth (PEG) Ratio | 0.00 | -4.22 | 1.80 | -0.14 | 1.42 |
| Enterprise Value Multiple | -16.41 | -37.28 | -56.14 | -22.19 | -116.53 |
| Enterprise Value | 910.91M | 1.28B | 1.43B | 812.32M | 986.11M |
| EV to EBITDA | -16.41 | -37.28 | -56.14 | -22.19 | -116.53 |
| EV to Sales | 29.93 | 24.16 | 21.99 | 13.18 | 11.49 |
| EV to Free Cash Flow | -19.20 | -23.37 | -34.25 | -23.34 | -23.88 |
| EV to Operating Cash Flow | -19.36 | -24.74 | -34.49 | -23.76 | -25.31 |
| Tangible Book Value Per Share | 8.54 | 10.35 | 7.43 | 8.23 | 9.19 |
| Shareholders’ Equity Per Share | 8.24 | 9.85 | 6.99 | 7.98 | 9.07 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.02 | 0.05 |
| Revenue Per Share | 0.48 | 0.92 | 1.20 | 1.16 | 1.61 |
| Net Income Per Share | -0.88 | -0.88 | -0.83 | -1.01 | -0.48 |
| Tax Burden | 0.78 | 0.96 | 1.05 | 0.98 | 0.95 |
| Interest Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.01 |
| Research & Development to Revenue | 1.33 | 0.82 | 0.68 | 0.88 | 0.59 |
| SG&A to Revenue | 1.67 | 1.01 | 0.78 | 0.79 | 0.54 |
| Stock-Based Compensation to Revenue | 0.02 | 0.05 | 0.01 | 0.01 | 0.01 |
| Income Quality | 0.66 | 0.98 | 0.92 | 0.63 | 1.45 |
Currency in TWD
